Zdrowie i gospodarka · 27/10/2022
FDA Hosts Public Workshop on Quantitative Brain Amyloid PET Imaging for Alzheimer's Disease
The FDA is hosting a public workshop to discuss the use of quantitative positron emission tomography (PET) measures of amyloid deposition in the brain for patients with suspected or confirmed Alzheimer's disease, as part of its evaluation of this technology in clinical trials and clinical use.